A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

Trial Profile

A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Ramucirumab (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms REGARD
  • Sponsors Eli Lilly; ImClone Systems
  • Most Recent Events

    • 29 Sep 2017 Results of subgroup analysis of Regard and Rainbow trial published in the Journal of Gastroenterology and Hepatology
    • 06 Jun 2017 Results (n=1020) of an exploratory analysis from RAINBOW and REGARD studies, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jan 2017 Results of subgroup analysis assessing STEPP across age subgroups using patient data from RAINBOW and REGARD trials, presented at the 2017 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top